In a small cohort of seven critically ill COVID‐19 patients (age 47–70 years; median age, 60 years) with severe symptoms (cytokine storm syndrome along with organ failure) at the Jena University Hospital in Germany, infliximab treatment (5 mg·kg−1 body weight between day 0 and 3 following admission) led to a rapid but temporary decrease in IL‐6, C‐reactive protein and LDH. Here, IL6 is linked to COVID-19.